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1. Overview 
 
This is a template for a deterministic compartmental model of TB transmission which is similar in structure to a 
number of previously published models. The model assumes that different strata mix homogenously (i.e. 
random mixing). The core TB model structure is shown in Figure 1. Model parameters (see Table 1 and 2) are 
based on previously published estimates, and are reviewed periodically. Interventions are also described. 
 
2. TB Model Core  
Disease progression 
Susceptible (S) individuals are infected at a rate λ = β(I+c*N) / T where β is the effective contact rate, I the 
number of smear positive and N the number of smear negative TB cases. c is the relative (lower) 
infectiousness of smear negative cases compared to smear positive cases, and T is the total population. A 
proportion α of newly infected individuals develop primary TB, a proportion (σ) become smear-positive (I) and a 
proportion 1-σ become smear-negative (N).  
 
Of those infected, 1-α become latently infected. Latent infected (L) individuals can progress to TB disease at 
rate ν for reactivation disease. A proportion of latent re-infected (α(1-x)) develop exogenous (reinfection) TB 
disease (where x defines the level of protection conferred by a previous infection). A proportion of these (σ) 
become smear-positive (I), 1-σ become smear-negative (N). We assume individuals who recover from smear 
positive (I) or smear negative (N) TB disease return to the Latent compartment where they are are at identical 
risk of developing TB disease via reactivation and following reinfection as the rest of individuals in that 
compartment. 
 
Individuals with prevalent TB disease experience an increased risk of mortality (μI or μN) that depends on 
smear status and model stratum (e.g. HIV/ART). 
 
Case detection and treatment 
Individuals with smear-positive TB disease are screened at rate γ, a proportion of those that are diagnosed 
with active disease (true positives) are linked onto care, η. Individuals with smear-negative disease are 
screened at a lower rate given by dγ .  
 
A proportion of these individuals (τ) complete treatment and are assumed to return to the latent compartment. 
Individuals can also naturally recover at rate r, after which they would also return to the latent compartment. 
Detected cases that do not complete treatment (1-τ) remain in their disease compartment (I or N). 
 
Individuals who do not have active TB disease are screened at a lower rate given by hγ. A proportion of those 
who are falsely diagnosed with active disease (false positives) are linked onto care, η.  
 
The diagnostic component of the core model includes parameters for the net sensitivity and specificity of 
different diagnostic algorithms (inputted by the user). Let Se#  and Se$  be the net sensitivities and weighted 
average based on coverage of different algorithms in a given year for smear positive and smear negative 
cases, respectively. Similarly, Sp# and Se$ are the specificities. 
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Figure 1a – schematic of core TB model 
 
Black arrows represent transitions between TB states, green arrows represent births, red solid arrows 
represent background deaths, red dashed represent TB deaths 
 
Post-Preventive	Therapy	Compartment	
Interventions	that	include	a	preventive	therapy	component	(provision	of	PT	as	part	of	ACF	in	HIV-	population,	provision	
of	PT	to	under	5	year	olds)	cause	a	movement	of	protected	individuals	to	the	post-preventive	therapy	compartment.	
Individuals	in	the	post-preventive	therapy	compartment	are	at	risk	of	re-infection,	but	not	reactivation	and	experience	
the	protective	effect	from	having	a	previous	infection.	The	movement	of	individuals	is	guided	by	a	p	factor,	which	
reroutes	individuals	following	infection	from	S	towards	the	post-PT	compartment	or	following	re-infection	from	L	
towards	post-PT.	
Individuals	with	latent	infection,	who	are	screened	for	TB	and	are	falsely	diagnosed	with	disease	(false	positives)	are	
assumed	to	be	cleared	of	their	infection	if	linked	onto	care	and	successfully	treated	and	therefore	move	to	the	post-PT	
compartment.		
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Figure 1b – schematic of core TB model with Post-preventive therapy compartment 
	
	
	
The	p	factor	is	an	age	dependent	parameter	that	is	calculated	for	specific	interventions	and	is	set	to	0	for	populations	
that	are	not	part	of	the	interventions.	
For	the	provision	of	PT	to	under	5	years	old	(see	interventions	section	for	more	details),	the	p	factor	is	calculated	as	
follows:	
Total	number	of	HH	u5s	protected	due	to	intervention	=	N	
Number	of	notified	adults*average	number	of	u5	in	household*0.304*intervention	cov(%)*linkage	of	INH(%)*complete	
INH(%)*0.55	
Total	number	of	all	u5s	that	would	be	infected	=	D	
Total	u5	Su5_(t=0)*λ(t=-1)	+	Lu5_(t=0)*λ(t=-1)	+	Pu5_(t=0)*λ(t=-1)	
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Number	of	u5s	that	move	from	S	to	post-PT:	Su5_(t=0)*λ(t=0)*p(t=0)	
Number	of	u5s	that	progress	to	disease:	Su5_(t=0)*λ(t=0)*α*(1-p(t=0))	
Number	of	u5s	that	progress	to	latent	infection:	Su5_(t=0)*λ(t=0)*(1-α)*(1-p(t=0))	
Therefore,	the	p	factor	is	applied	based	on	p=N/D	(above)	only	for	the	0-4	year	old	age	bin	and	is	set	to	0	for	all	other	
ages.	
 
3. Age structure 
 
TIME v1.0 is parameterised in 5 year age-bins and assumes homogeneous mixing among all subpopulations 
and across all ages.  
 
A childhood structure is included in order to capture the epidemiological differences in the paediatric age 
groups (<15 years old) compared to the adult population (>15 years old). 
 
The parameters affected in paediatric age groups are: 
a. Progression to disease (combination of risk of progression to disease and risk of rapid progression) 
b. Proportion progressing to smear positive disease 
c. Background TB-specific mortality 
d. BCG vaccination 
 
Each of these parameters is adjusted using RRs based on review of the literature and are relative to adult TB. 
An exception to this is BCG vaccination, which is applied to the progression parameters in paediatric age 
groups as a reduction in risk of progression to disease. Each paediatric age group (0-4, 5-9, 10-14) are 
adjusted with a different RR, informed by the literature review. 
 
The Epidemiology tab in TIME Impact holds a section for childhood TB. Here, the user is able to make 
changes to paediatric TB by adjusting the RR for the risk of rapid progression in the 10-14 year old age group. 
All other RR parameters change proportionately to the adjustment made. 
 
 
4. Model strata  
 
TIME v1.0 is stratified by HIV/ART status (number of strata is the same as existing AIM structure) (1-3), 
Treatment status (2 strata), MDR status (2 strata). While the TIME model population is also stratified by 1-year 
age band and sex (as existing Spectrum), TIME is currently parameterised in 5 year age groups.   
 
 
 
Treatment History strata 
TIME v1.0 is stratified by treatment history, which facilitates modelling the epidemic and interventions related to 
MDR. There is evidence that the rates of TB disease following reinfection (strong evidence) and 
reactivation/relapse (less strong) are higher in individuals with a history of TB treatment. However, progression 
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and infection parameters are currently assumed not to differ by treatment history status, as is convention in 
most models.   
 
There are two structural effects of stratification by treatment history. Firstly, is that individuals recovering after 
diagnosis and treatment ( (d)γSeητ ) in the treatment naive strata are assumed to move to the Latent 
compartment in the past treatment strata. This is shown by the solid purple arrows in figure 2. Compartments 
represent treatment naive individuals (with subscript N, e.g. LN) or individuals with a past treatment history (with 
subscript P, e.g. LP). 
 
To follow the rather strict definition of ‘past treatment’ (which is usually >2 weeks of exposure to TB drugs), 
TIME Impact assumes patients started on unsuccessful TB treatment ((d)γSeη(1 − τ)) move from IN to IP and 
NN to NP. This is shown by the purple dotted lines in figure 2. This makes the simplifying assumptions that all 
patients who start treatment receive at least two weeks of drugs, and that all smear positive patients receiving 
unsuccessful treatment remain smear positive. Unsuccessfully treated cases are not counted as additional new 
incident cases in TIME Impact to reflect the method used by WHO for counting cases. When cases default 
from treatment, they remain in the prevalent pool. When cases who have defaulted from treatment are 
rediagnosed, they are counted as retreatment cases as per WHO guidelines. 
 
 
MDR strata 
TIME includes 2 strata based on MDR status, which is the most clinically and policy relevant distinction based 
on drug sensitivity. Adjustments in the TIME Impact model structure include: 
- Acquired resistance  
The model allows for acquired resistance. A proportion of those starting first line as initially non-MDR TB 
disease episode (as per standard DST) are assumed to progress to active disease where MDR is the dominant 
strain. The underlying process can be that a small number of pre-existing spontaneous MDR mutations were 
uncovered by first line treatment, or the more classic view that insufficiently effective first line treatment (e.g. 
through imperfect adherence) creates MDR. In the model, acquiring MDR moves individuals from ISEN or NSEN 
to the corresponding MDR disease compartment (IMDR or NMDR). The rate of acquiring MDR is determined by 
parameter ksi (ξ), which is applied directly to a term of non-MDR cases that are diagnosed and started on 
treatment γSe#η ./01 + dγSe$η 3/01. We assume no MDR is acquired in the absence of treatment. Once the 
patient has moved to the MDR compartment, we assume they experience the same (MDR specific) linkage to 
care and second line treatment success as all MDR cases.  
 
Note that ξ is applied directly to the proportion detected and started on treatment ((4)γSeη), and that the 
proportion of successful treatment (τ) is therefore applied to those not acquiring resistance ((4)γSeη*(1-ξ)). 
This allows the model to use values for ξ based on data, but will cause a slight overestimation of treatment 
failure.  
 
 
- Initial infection with MDR 
There are 2 annual risks of infection (λ= beta*(I+c*N) / P), one for each MDR stratum. The λ term for the MDR 
strata is adjusted with a relative fitness parameter phi φ, leading to (λMDR= beta*(IMDR+c*NMDR) / P)*φ.  
 
We assume relative fitness only affects the transmission parameter λ (i.e. risk of first infection and re-infection). 
We assume it does not affect the protection offered by a previous infection, the rate of rapid progression to TB 
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disease (α) or the rate of reactivation TB disease (ν). We also assume it does not affect the proportion of active 
disease that is smear positive (which is already implicitly included in relative fitness parameter).  
  
- Superinfection (defined as reinfection with strain of different drug resistant profile) 
In TIME Impact, it is assumed that superinfection occurs. Superinfection can result into either rapid progression 
to disease, or a latent infection at risk of reactivation in the other MDR stratum.  
 
Superinfections - Rapid Progression: Superinfections that progress to disease (λMDR	or	Non_MDR	α 1 − x ) are 
assumed to move to the disease compartment that matches the drug resistant profile of the superinfection 
strain, irrespective of the MDR status of the latent or reinfection strain. 
 
Superinfections - Reactivation: We do not explicitly model mixed infections. Superinfections that do not 
immediately progress to disease are therefore assumed to move to one of the latent strata. In the absence of 
data and for simplicity, the proportion of non-progressing superinfections that move to the latent MDR 
compartment (ί) is assumed to be based on the relative fitness (φ) parameter, and calculated as ι = CDEC 
In summary, the following rules apply (only terms in bold are included in equations, as other terms would keep 
individuals in same compartment): 
1. Latentsens + sens reinf → Latentsens and LatentMDR + MDR reinf → LatentMDR  
2. Latentsens  + MDR reinf → ί*new infections to LatentMDR, (1-ί)*new infection stay in Latentsens  
3. LatentMDR + sens reinf → ί*new infections stay in LatentMDR, (1-ί)*new infection to Latentsens  
 
- Drug sensitivity testing  
TIME has an explicit DST parameter, defined as the proportion of all diagnosed cases that receive a DST, by 
treatment history. This allows inclusion of usually reasonably strong country data, if available. Only if a 
diagnosed true drug-sensitive case receives a false positive result on DST or a true MDR case receives a true 
positive results on DST can they receive MDR treatment.  
 
- Treatment success in MDR with first-line drugs  
Individuals that don’t receive a DST, MDR status remains unknown and they are started on first-line treatment. 
The literature suggests that MDR cases do experience some treatment success with first-line drugs, though it 
is lower than for drug sensitive cases (4). 
 
New (IG_H	IJ	NG_H) MDR cases who get diagnosed with TB disease (non-MDR) and are linked to non-MDR 
care (ηK), but do not receive a DST 1 − ψH  or receive a false negative result on DST (MN O − PQR ) enter the 
non-MDR care pathway.  
A proportion of these are cured with first-line drugs, but at a lower treatment success than is experienced by 
pan-sensitive cases τK	×	TTH  and enter the latent, previously treated compartment (LG_V), where they are at 
risk for reactivation. Those that fail treatment 1 − τK	×	TTH  move to active, previously treated, retaining 
their smear status (IG_V	IJ	NG_V). 
Similarly, previously treated (IG_V	IJ	NG_V) MDR cases who get diagnosed with TB disease (non-MDR) and are 
linked to non-MDR TB care (ηK), but do not receive a DST (1 − ψV) or receive a false negative results on DST 
(MN O − PQR )	enter the non-MDR care pathway. They experience a lower treatment success compared to pan-
sensitive cases and new MDR cases that are being treated by first-line drugs (τK	×	TTV).  Those that are 
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successfully treated enter the latent, previously treated compartment (LG_V) and those that fail treatment 
remain in the active disease compartment, retaining their smear status (IG_V	IJ	NG_V).  
Interactions between treatment history and MDR strata 
There are various interactions between treatment history and MDR status, also reflecting the proportion of 
cases that receives DST.   
 
New patients with MDR 
In the model treatment naïve patients are assumed to only be MDR if they develop disease following a 
(reactivation of) new or super-infection with an MDR strain. All other MDR TB, be it acquired or initially treated 
with first line drugs, is assumed to come from the ‘previously treated’ strata.  
 
Drug sensitivity testing and treatment status 
New MDR cases who are diagnosed with TB disease, but do not receive DST or receive a false negative result 
on DST, are assumed to enter the non-MDR TB care pathway. A proportion of these are assumed to not start 
treatment (1-linkage to care in the non-MDR TB care pathway) and are assumed to remain in the ‘no previous 
treatment, MDR’ disease compartment.  
 
As stated earlier, MDR cases that do not receive a DST enter the non-MDR care pathway where they 
experience some treatment success with first-line drugs, but less than those with drug-sensitive TB. MDR 
cases that are successfully treated with first-line drugs are moved to the Latent previously treated 
compartment. New MDR cases (IM or NM) that fail treatment with first-line drugs enter the previously treated 
active disease compartment, retaining their smear-status.  
 
Disease type and treatment status  
The model currently assumes that cases that acquired (or uncovered) MDR during treatment retain their 
disease type status (smear positive or negative) as they move from the non-MDR to MDR, and from ‘no 
previous treatment’ to ‘previously treated’ stratum.  
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Figure 2 – Schematic of core TB model with Treatment history stratum 
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Figure 3. Schematic of MDR stratified core model 
Arrows in figure shows all flows between compartments in MDR stratified model. Blue arrows indicate changes in MDR status.  
● Compartments or parameters that apply specifically an MDR stratum are indicated by subscripts, e.g. LS for Latent non-MDR (‘sensitive’) and LM 
for Latent MDR.  
● Force of infection with MDR strain has penalty for loss of fitness: λMDR= beta*(IMDR+c*NMDR) / P)*φ 
● Flow from non-MDR Latent (LS) to active MDR disease (IM or NM) and vice versa represent superinfections that progress rapidly to disease.  
● Arrows between Latent (L) compartments represent non-progressing superinfection strains (as described above, flow determined by ί) 
● Dashed blue lines represent acquired drug resistance (ξ).  
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Integration of HIV model  
HIV/ART model (AIM) 
TIME integrates with the existing Spectrum HIV/ART structure to ensure consistency between HIV and TB 
models. The following strata are implemented and are used to specify HIV status:  
1. HIV negative 
2. HIV positive, not on ART 
3. HIV positive, on ART for 0-6 months, 7-12 months and on ART for greater than year. The choice of ‘on-
ART’ strata is motivated by mortality data prepared by the Idea consortium, which indicates distinct 
mortality patterns in these three stages following enrolment on ART. 
 
Each HIV-positive category has seven CD4 stages: CD4 < 50 cells/uL, 50-99, 100-199, 200-249, 250-349, 
350-499 and > 500 cells/uL. The following HIV-related parameters vary as a function of CD4 count: 
progression to lower CD4 counts, HIV-specific mortality, probability of initiating ART, and HIV 
infectiousness. Spectrum’s ART categories are also structured by the same seven CD4 categories, but they 
are used only to keep track of CD4 at ART initiation. Spectrum does not model recovery of CD4 count 
following ART. Many of the HIV parameters are also stratified by sex and age. These parameters are then 
represented in a table structured by sex and 10-year age bins.  
 
The following equations describe the demographic HIV model in Spectrum. S denotes individuals 
susceptible to HIV, I individuals who are HIV positive but not yet receiving ART and A HIV positive 
individuals receiving ART. Each of the variables is structured by time (t) and age (a). I is further subdivided 
by CD4 category (c=1...7), whereas A is subdivided by CD4 category (c=1...7) and duration of ART 
(d=1,2,3).  
 
The following parameters are used to describe the demographical and HIV processes:  
μ(a) – age-specific background mortality,  
H(t,a) time and age-specific number of new infections from Spectrum,  
H(t,a,c) time, age and CD4 specific number of new infections from Spectrum,  
β(a,c) – age and CD4 specific HIV mortality,  
β(a,c,d) – age, CD4 and ART duration specific HIV mortality,  
ϕ(a,c) age and CD4-specific progression rate,  
a(t,a,c) time, age and CD4 specific ART initiation numbers from Spectrum,  
σ(d) specifies movement to subsequent ART categories.  
 
For d=1 and d=2 σ(d)=2, modelling an average duration of 6 months. Each parameter can also vary by sex 
(not shown in equations). 
 
HIV model equations 
Susceptible (S) !" #,%!# +	!" #,%!% 		=  −	µ a S t, a − H(t, a) 
HIV+ not on ART (I) !0 #,%,1!# +	!0 #,%,1!% 		=  −	 µ a + β a, c + ϕ a, c I t, a, c + ϕ a, c − 1 I t, a, c − 1 + H t, a, c − 	a(t, a, c)	 
HIV+ on ART (A) 
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!7 #,%,1,!!# +	!7 #,%,1,!!% 		=  −	(µ a + β a, c, d + σ(d))A t, a, c + σ(d − 1)A t, a, c, d + a(t, a, c) 
 
Integration of HIV model with TB strata/states  
New HIV infections and ART initiations:  
AIM calculates the age/sex group specific number of incident HIV infections that occur during the time step, 
and distributes these evenly across the HIV negative TB states and strata, weighted by size of the 
population in that state/stratum. It does not take into account: 
- Risk of HIV infection during TB disease. This may not be highly relevant given the size of the 
compartment (<1% of population in almost every country) 
- TB as an indication of ART eligibility. HIV positive individuals with TB disease are eligible for ART, 
regardless of CD4 count; therefore, their likelihood of being initiated on ART is higher compared to 
other HIV positive individuals in their respective CD4 stratum. However, TIME Impact includes an 
intervention to reflect screening of HIV in active TB cases and linking HIV+ into ART care (see 
Interventions chapter).  
HIV progression and TB states 
If an HIV positive individual moves between TB states, they automatically transfer to the corresponding 
CD4/ART category within that new TB state, and continue with the same HIV progression.  
HIV/TB mortality 
All HIV positive categories experience a higher background mortality. The value for HIV specific mortality is 
drawn from AIM, and is CD4 dependent. It would be inappropriate to apply the default values, which include 
deaths due to TB, to non-TB disease states (Susceptible and Latent) in the TB model, as these populations 
are not at risk of dying from the disease. To adjust for this, the default AIM mortality rate is reduced by 25% 
(global estimate of all HIV deaths that are due to TB, (5)).  
 
ART allocation 
Total number of new ART allocations (which comes from AIM per CD4 category) gets divided in proportion 
to population size and mortality of the different compartments. 
 
That is, start_art(x)=(W1(x)+W2(x))/2*new_art 
 
Where x is the state label and W1 is the size of x relative to all eligible for ART and W2 the proportion of all 
mortality among those eligible that happen in x. 
 
Impact of HIV and ART on TB natural history parameters 
All natural history TB parameters can be modified by HIV status, though by default, smear conversion rate 
and MDR fitness and acquisition parameters are set as the same.  
 
The parameters for rapid progression to TB, the reactivation rate and the protection offered by prior infection 
are dependent on HIV status and CD4 category. Following a model by Williams et al, the user specifies two 
relative risks: 
 
RR1: the initial change in risk attributable to HIV infection (i.e. in the CD4>500 category).  
RR2: the change in risk with each 100-cells/uL change in the CD4 count.  
TIME	Impact:	Technical	Appendix	
	
13	
 
The final parameter value is calculated as P(HIV-) x RR1 x RR2 CD4. The value CD4 is taken as (500 – 
midpoint value for that CD4 strata)/100. E.g. for the 350-500 strata, the mid-point is 425, so the value is 
0.75.  
 
The impact of ART is to reduce the difference between the parameter value for that CD4 strata and the HIV 
negative value for that parameter. The effect increases with time spent on ART.  
 
Default values for these parameters and references can be found in the table 2.  
 
Screening for disease 
Diseased individuals enter the screening population at a rate of γ and follow a diagnostic algorithm with a 
net sensitivity of Se=_? for smear positive disease and Se=_@ for smear negative disease. A relative screening 
rate of d is applied to smear negative TB. A proportion ψB (for treatment naïve) or  ψC (for previously 
treated) of cases will receive a DST with a test sensitivity of SeD and a specificity of SpD. A proportion η=	(for 
drug sensitive TB) and ηD (for MDR TB) are linked onto first or second line care, respectively.  
Individuals with pan-sensitive TB disease, are therefore diagnosed and linked onto first-line care at a rate of γSe=_?ψBSpDη= for those that receive a DST or γSe=G(1 − ψB)η= for those that do not receive a DST.  
A proportion of those who are treated successfully τ" enter the latent, previously treated compartment. 
Those that fail treatment (1 − τ") either move to the active disease previously treated compartment (if they 
were treatment naïve) or remain in the active disease previously treated compartment if they were already 
previously treated, retaining their smear status. A proportion of cases with drug sensitive TB disease that 
are linked onto first-line care ξ develop MDR-TB and are moved to the previously treated active MDR TB 
compartment, retaining their smear status. 
Individuals with true drug sensitive TB may receive a false positive results on DST and are therefore falsely 
linked onto second line care γSe=_?ψ 1 − SpD ηD. It is assumed that these individuals experience the same 
treatment success probability as those with MDR TB who are linked onto second line care τJ. 
Individuals with MDR TB disease can only be linked onto appropriate second line care if they receive a DST 
and if the results are true positive. Individuals with false negative result on DST are linked onto first-line 
care, where they experience a reduced treatment success probability: γSe=_?ψB(1 − SeD)η= τ"	×	RRB  for 
treatment naïve individuals and γSe=_?ψC(1 − SeD)η= τ"	×	RRC  for previously treated individuals. 
Note: Smear positive or negative cases that are not picked up by the net sensitivity of the algorithm (i.e. 1 − Se? for smear positive and 1 − Se@ for smear negative) are undetected (false negative) cases and remain 
in their respective disease compartments. 
Individuals from the susceptible compartment that enter the screening population at a rate of hγ can be false 
positive cases (1 − Sp?	×	Sp@ ). These individuals remain in the susceptible compartment, ignoring any 
protective effects that may be offered while the individuals are on treatment.  
Individuals from the latent compart also enter the screening population at a rate of hγ. However, those that have been 
screened for TB, are false positive, have been linked onto first-line care and have completed treatment (hγ(1 −Sp?	×	Sp@ )η=τ=) are considered cured of the Mtb latent infection and move to the Post-preventive therapy box, 
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where they are at risk of reinfection but not reactivation. Note that this does not apply to individuals with latent MDR 
infection. 
 
5. Full model equations (excluding HIV strata and interventions) 
 
Table 1. Legend for model parameters used in equations 
Epidemiology/natural history 
β, effective contact rate  
c, relative infectiousness of smear-negative cases 
λ, annual rate of infection = β(I+c*N) / T (I=SSpos, N=SSneg, T=total population) 
α, proportion of infections developing primary TB 
ν, rate at which latently infected individuals develop active TB disease  
σ, proportion of cases developing smear positive TB disease  
x, protection provided by prior infection* 
r, self cure rate 
θ, rate of conversion  from SSneg to SSpos disease (N to I)  
μ
I
, TB disease mortality rate (SSneg) 
μ
N
, TB disease mortality rate (SSpos) 
Care and control  
η, proportion linked into care 
γ, screening rate 
d, relative screening rate of smear-negative cases  
τ, treatment success, by MDR status  
h, relative screening rate of individuals without active TB disease (susceptible and latent) 
p, protection from preventive therapy 
Se, sensitivity of screening, by smear status and MDR status 
Sp, specificity of screening, by smear status and MDR status 
MDR specific parameters 
 ξ, % acquiring MDR Risk acquiring MDR under treatment (% per treatment episode) 
 φ, relative fitness of MDR strains  
Ί, proportion of non-progressing superinfections that move to the latent MDR compartment = NOPN 
ψ, proportion of diagnosed MDR TB cases that receive a DST (separated by treatment history 
status ψN & ψP)  
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Model equations 
 
Susceptible population (S) !"!# = +ω − λ" + λJ + 	µ S  
 
Non-MDR, drug susceptible strains 
Latent treatment naïve !ST_U!#  =  − ν + λ"(α 1 − x 1 − p + p) + 	λJα 1 − x + λJ 1 − α 1 − x ί + µ + hγ 1 − Sp?	×	Sp@ η=τ= L"_[ +	λ" 1 − α 1 − p S	 + rI"U + rN"U	 +λ"(1 − α)(1 − x)(1 − ί)LJ_[ + λ" 1 − α (1 − ^) 1 − p P=_B 
 
Latent previously treated  !ST_`!#  =  − ν + λ" α 1 − x 1 − p + p + 	λJα 1 − x + λJ 1 − α 1 − x ί + µ + hγ 1 − Sp?	×	Sp@ η=τ= L"_a +	 r + γSe=_?ψCSpDη= 1 − ξ τ" + γSe"_b(1 − ψC)η= 1 − ξ τ" + γSe=_?ψC 1 − SpD ηDτJ I"_a + r + dγSe"_cψCSpDη= 1 − ξ τ" + dγSe"_c(1 − ψC)η= 1 − ξ τ" + dγSe=_@ψC 1 − SpD ηDτJ N"_a	 +λ" 1 − α 1 − x 1 − ί LJ_a +	 γSe=_?ψBSpDη= 1 − ξ τ" + γSe"_b(1 − ψB)η= 1 − ξ τ" + γSe=_?ψB 1 − SpD ηDτJ I"_[ + dγSe=_@ψBSpDη= 1 − ξ τ" + dγSe"_c(1 − ψB)η= 1 − ξ τ" + dγSe=_@ψB 1 − SpD ηDτJ N"_[	 +	λ" 1 − α (1 − ^) 1 − p P=_C 
 
Active Smear Positive treatment naïve  !0T_U!#  = 	λ"ασ 1 − p S + νσ + λ"ασ 1 − x 1 − p L"U + λ"ασ 1 − x 1 − p P=_B + 	θN"_[ + 	λ"α(1 − x)σLJ_[		 −(µ + µ0 + r + γSe=_?ψBSpDη= + γSe"_b(1 − ψB)η= + γSe=_?ψB 1 − SpD ηD)I"_[ 
 
Active Smear Positive previously treated  !0T`!#  = 	 νσ + λ"ασ 1 − x 1 − p L"` + λ"ασ 1 − x 1 − p P=e + θN"` + 	λ"α 1 − x σLJ` +	(γSe=GψBSpDη= 1 − ξ 1 − τ= + γSe"_b(1 − ψB)η= 1 − ξ 1 − τ= + γSe=GψB 1 − SpD ηD(1 − τJ))I"_[		 − µ + µ0 + r + γSe=_?ψCSpDη= 1 − ξ τ" + γSe"f(1 − ψC η= 1 − ξ τ" + γSe=GψC 1 − SpD ηDτJ+ γSe=GψCSpDη=ξ + γSe"_b(1 − ψC)η=ξ)I"_a 
 
Active Smear Negative treatment naïve  ![TU!#  = 	λ"α 1 − σ 1 − p S + ν 1 − σ + λ"α 1 − σ 1 − x 1 − p L"U +λ"α 1 − σ 1 − ^ 1 − p P=g + 	λ"α 1 − x 1 − σ LJU		 −	(θ + µ + µ[ + r + dγSe=hψBSpDη= + dγSe"_c(1 − ψB)η= + dγSe=_@ψB 1 − SpD ηD)N"_[ 
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Active Smear Negative previously treated  ![T`!#  = 	 ν 1 − σ + λ"α 1 − σ 1 − x 1 − p L"` + λ"α 1 − σ 1 − ^ 1 − p P=_C + 	λ"α 1 − x 1 − σ LJ_a +	 dγSe=hψBSpDη= 1 − ξ 1 − τ= + dγSe"i(1 − ψB η= 1 − ξ 1 − τ=+ dγSe=_hψB 1 − SpD ηD 1 − τJ )N"_[		 − θ + µ + µ[ + r + dγSe"iψCSpDη= 1 − ξ τ= + dγSe"i(1 − ψC η= 1 − ξ τ" + dγSe=GψC 1 − SpD ηDτJ+ dγSe"_cψCSpDη=ξ + dγSe"_c(1 − ψC)η=ξ)N"_a 
 
Post-preventive therapy, treatment naïve  jk=_Bjl = λ"pS + (λ"p + hγ 1 − Sp?	×	Sp@ η=τ=)L=_B − (λ" 1 − x 1 − p + λDα 1 − x + λD 1 − α 1 − x ί+ µ)P=_B 
 
 
Post-preventive therapy, previously treated jk=_Cjl = (λ"p + hγ 1 − Sp?	×	Sp@ η=τ=)L=_C − (λ" 1 − x 1 − p + λDα 1 − x + λD 1 − α 1 − x ί + µ)P=_C 
 
 
MDR strains 
 
Latent treatment naïve !Sn_U!#  =  − ν + λ"α 1 − x + 	λJα 1 − x + λ" 1 − α 1 − x (1 − ί) + µ LJ_[ +	λJ 1 − α S	 + rIJ_[ + rNJ_[ 	+ λJ 1 − α 1 − x ί L"U + (λDα 1 − x + λD 1 − α 1 − x ί)	P=_B 
	
Latent previously treated  !Sn_`!#  =  − ν + λ"α 1 − x + 	λJα 1 − x + λ" 1 − α 1 − x (1 − ί) + µ LJ_a +	 r + γSe=_?ψCSeDηDτJ + γSe=_? 1 − ψC η= τ"	×	RRC + γSe=_?ψC(1 − SeD)η= τ"	×	RRC IJ_a	 + r + dγSe=_@ψCSeDηDτJ + dγSe=_@ 1 − ψC η= τ"	×	RRC + dγSe=_@ψC 1 − SeD η= τ"	×	RRC NJ_a		 +(λJ 1 − α 1 − x ί)L"_a +	 γSe=_?ψBSeDηDτJ + γSe=_? 1 − ψB η= τ"	×	RRB + γSe=_?ψB(1 − SeD)η= τ"	×	RRB IJ_[	 +	(dγSe=hψBSeDηDτJ + dγSe=h 1 − ψB η= τ"	×	RRB + dγSe=hψB 1 − SeD η= τ"	×	RRB )NJU +λDα 1 − x + λD 1 − α 1 − x ί + µ)P=_C		 
	
Active Smear Positive treatment naïve !0n_U!#  = 	(λJασ)S + (νσ + λJασ(1 − x))LJ_[ + 	θNJ_[ + 	λJα(1 − x)σL"_[		 −(µ + µ0 + r + γSe=_?ψBSeDηD + 	γSe=_? 1 − ψB η= + γSe=_?ψB(1 − SeD)η=)IJ_[ 
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Active Smear Positive previously treated  !0n_`	!#  = 	 νσ + λJασ 1 − x LJ` + 	θNJ` +	λJα 1 − x σL"` +(γSe=_?ψBSeDηD 1 − τJ + 	γSe=G 1 − ψB η= 1 − τ"	×	RR[ + γSe=_?ψB(1 − SeD)η= 1 − τ"	×	RR[ )	IJ_[	 +(γSe=GψBSpDη=ξ + γSe"f(1 − ψB)η=ξ)I"U 	+ (γSe=GψCSpDη=ξ + γSe"_b(1 − ψC)η=ξ)I"_a	 −(µ + µ0 + r + γSe=_?ψCSeDηDτJ + γSe=_? 1 − ψC η= τ"	×	RRC + γSe=_?ψC(1 − SeD)η= τ"	×	RRC )IJ_a 
	
Active Smear Negative treatment naïve  ![n_U!#  = 	(λJα(1 − σ))S + (ν(1 − σ) + λJα(1 − σ)(1 − x))LJ_[ + 		λJα(1 − x)(1 − σ)L"_[		 −(θ + µ + µ[ + r + dγSe=hψBSeDηD + 	dγSe=h 1 − ψB η= + dγSe=hψB 1 − SeD η=)NJ_[ 
 
Active Smear Negative previously treated  ![n_`	!#  = 	 ν 1 − σ + λJα 1 − σ 1 − x LJ` +	λJα 1 − x 1 − σ L"` +(dγSe=hψBSeDηD 1 − τJ + 	dγSe=h 1 − ψB η= 1 − τ"	×	RR[+ dγSe=hψB 1 − SeD η= 1 − τ"	×	RR[ )NJ_[ +(dγSe=hψBSpDη=ξ + dγSe"_c(1 − ψB)η=ξ)N"_[ 	+ (γSe"_cψCSpDη=ξ + dγSe"_c(1 − ψC)η=ξ)N"_a	 −(θ + µ + µ[ + r + dγSe=hψBSeDηDτJ + dγSe=_@ 1 − ψC η= τ"	×	RRC+ dγSe=_@ψC 1 − SeD η= τ"	×	RRC )NJ_a 
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6. Model parameters  
Default value and ranges for TIME Impact model parameters 
Table 2 below shows the current default parameter values and recommended ranges. The sources currently reflect values and ranges 
used in other models. As time allows, these will be updated with more empirical sources. The values in the grey boxes are the values 
currently used in TIME. 
 
Table 2. Default values for parameters 
	 Point	
estimate	
Lower	
bound	
Upper	
bound	 Source	 Notes	
Progression	to	TB	
HIV-	
Develop	Primary	TB	(%)	 11.5	 9	 14	 (6)	 	
14	 5	 25	 (7)	 	
	 8	 15	 (8)	 	
11.5	 8	 15	 (6)	(8)	 	
Reactivation	rate	(%/year)	 0.1	 0.03	 0.24	 (6)	 	
0.11	 0.05	 0.25	 (7)	 	
	 0.01	 0.1	 (8)	 	
0.1	 0.01	 0.25	 (6)	(7)	(8)	 	
Protection	provided	by	prior	infection	(%)	 65	 37	 85	 (6)	 	
72	 60	 100	 (7)	 	
TIME	Impact:	Technical	Appendix	
	
19	
	 40	 90	 (8)	 	
65	 37	 90	 (6)	(8)	 	
Risk	Ratio	parameter	1	
Develop	primary	TB	(%)	 2.6	 2.11	 3.2	 (9)	 	
Reactivation	rate	(%/year)	 2.6	 2.11	 3.2	 (9)	 	
Protection	provided	by	prior	infection	(%)	 0.8	 0.6	 1	 (6)	 	
	
Risk	Ratio	parameter	2	
Develop	primary	TB	(%)	 1.36	 1.3	 1.42	 (10)	 	
Reactivation	rate	(%/year)	 1.36	 1.3	 1.42	 (10)	 	
Protection	provided	by	prior	infection	(%)	 -1.3	 -2	 -1	 (6)	 	
Smear	status	
HIV-	
Cases	developing	SSpos	TB	(%)	 62	 42	 80	 (6)	 	
	 40	 50	 (11)	 	
	 40	 80	 (8)	 	
45	 40	 50	 (11)	 Point	estimate	taken	as	midpoint	
Relative	infectiousness	SSneg	TB	(%)	 22	 16	 32	 (12)	 	
22	 10	 30	 (7)	 	
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22	 12	 37	 (6)	 	
22	 10	 37	 (6)	(7)	 	
Smear	conversion	rate	(%/year)	 1.5	 1	 2.3	 (6)	 	
1.5	 0.7	 2	 (8)	 	
2	 1	 3	 (7)	 	
1.5	 0.7	 3	 (7)	(8)	 	
HIV+	(CD4>500)	
Cases	developing	SSpos	TB	(%)	 45	 23	 68	 (6)	 	
	 24	 61	 (13)	 	
32.7	 21.9	 42.5	 (6)	(11)	 Assuming	proportion	between	HIV-	and	HIV+	from	
(6)	
Relative	infectiousness	SSneg	(%)	 22	 10	 37	 (6)	(7)	 Assuming	same	as	HIV-	
Smear	conversion	rate	(%/year)	 2.25	 1.5	 3	 Default	 	
Recovery	
HIV-	
Self	cure	rate	(%/year)	 20	 15	 25	 (6)	 	
	 	 10	 25	 (8)	 	
	 20	 10	 25	 (6)	(8)	 	
HIV+	(CD4>500)	
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Self	cure	rate	(%/year)	 10	 6	 16	 (6)	 	
TB	Mortality	
HIV-	
TB	morality	rate	(SSpos)	(%/year)	 30	 21	 41	 (6)	 	
	 30	 20	 40	 (8)	 	
	 30	 20	 41	 (6)	(8)	 	
TB	mortality	rate	(SSneg)	(%/year)	 21	 18	 25	 (6)	(8)	 	
HIV+	(CD4>500)	
TB	mortality	rate	(SSpos)	(%/year)	 60	 40	 82	 (6)	(8)	 Assume	double	HIV-	
TB	mortality	rate	(SSneg)	(%/year)	 42	 36	 50	 (6)	(8)	 Assume	double	HIV-	
MDR	
HIV-	
Relative	fitness	of	MDR	strains	(%)	 73	 58	 85	 (6)	 	
Risk	acquiring	MDR	under	treatment	(%	per	
treatment	episode)	
1.4	 1	 1.7	 (14)	 	
Treatment	success	when	using	FL	for	MDR	
treatment	naive	
0.61	 0.53	 0.70	 (4)	 	
Treatment	success	when	using	FL	for	MDR	
previously	treated	
0.45	 0.35	 0.58	 (4)	 	
HIV+	(CD4>500)	
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Relative	fitness	of	MDR	strains	(%)	 73	 58	 85	 (6)	 Assume	same	as	HIV-	
Risk	acquiring	MDR	under	treatment	(%	per	
treatment	episode)	
1.4	 1	 1.7	 (14)	 Assume	same	as	HIV-	
Treatment	success	when	using	FL	for	MDR	
treatment	naive	
0.61	 0.53	 0.70	 (4)	 	
Treatment	success	when	using	FL	for	MDR	
previously	treated	
0.45	 0.35	 0.58	 (4)	 	
Protection	offered	by	ART	%	reduction	of	impact	of	HIV	
Progression	
ART	<6m	(%)	 20.4	 15.75	 26.83	 (15)	 Assume	linear	interpolation	between	0	at	0	months	
and	70	at	12	months	
ART	7m-12m	(%)	 55.4	 42.75	 72.83	 (15)	 Assume	linear	interpolation	between	0	at	0	months	
and	70	at	12	months	
ART	>1	year	(%)	 70	 54	 92	 (15)	 	
81	 62	 91	 (16)	 	
70	 54	 92	 (15)	 Assume	plateau	after	12	months	
Mortality	
ART	<6m	(%)	 23.2	 10.7	 27.7	 (15)	 Assume	linear	interpolation	between	0	at	0	months	
and	79.5	at	12	months	
ART	7m-12m	(%)	 62.9	 50.7	 75.2	 (15)	 Assume	linear	interpolation	between	0	at	0	months	
and	79.5	at	12	months	
ART	>1	year	(%)	 	 64	 95	 (15)	 	
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	 79.5	 64	 95	 (15)	 Point	estimate	taken	as	midpoint	between	ranges	
provided;	assuming	plateau	after	12	months.	
Care	and	control	
Effective	contact	rate	(n/year)	 22	 0	 ∞	 	 Not	bounded	a	priori	
	
Table	3,	below,	shows	the	parameters	for	paediatric	TB.	The	RRs	shown	are	relative	to	adult	parameters.	
Table	3.	Default	RR	and	risks	for	paediatric	TB.	
Parameter	and	age	group	 RR	 Paediatric	risk	 Ref	
Risk	of	rapid	progression	 (6,	8,	17)	expert	opinion	
10-14	years	old	 0.47	 5.4%	 	
5-9	years	old 1.18	 13.6%	 	
0-4	years	old	 2.22	 25.5%	 	
Risk	of	smear	positivity	 (11,	18,	19)	
10-14	years	old 0.67	 30.2%	 	
5-9	years	old 0.34	 15.3%	 	
0-4	years	old 0.02	 0.7%	 	
Mortality	rate,	Smear	positive	 Expert	opinion	
10-14	years	old	 1	 30	 	
5-9	years	old	 1	 30	 	
0-4	years	old	 2	 60	 	
Mortality	rate,	Smear	negative	 Expert	opinion	
10-14	years	old	 1	 21	 	
5-9	years	old	 1	 21	 	
0-4	years	old	 2	 42	 	
	
Another	important	parameter	in	paediatric	TB	is	protection	offered	by	BCG	in	vaccinated	children.	Overall	(extrapulmonary	and	pulmonary)	weighted	
average	of	BCG	protection	is	56.24%	(39%-72%)	(20)	and	is	applied	to	the	progression	parameters	of	paediatric	age	groups.	BCG	can	be	turned	on	all	
via	a	toggle	switch	based	on	country-specific	policy.	
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7. Interventions 
Methods  
There are 2 ways of implementing interventions in TIME. Firstly, one can use the intervention matrix by 
providing intervention information such as impact size, sensitivity of screening algorithms (if needed) and 
time-dependent parameters (eg. Coverage). Secondly, the user can formulate a custom intervention directly 
by changing the Care and Control parameters.  
 
Intervention Matrix 
TIME offers an intervention matrix that explicitly shows which model parameters are changed by each 
intervention, and by how much. The population wide impact depends on this intervention matrix, the 
proportion of the population that is covered by the intervention at a given time. The interventions currently 
included in TIME are listed and their related assumptions are listed below. 
 
Increased Case Detection (non-MDR) 
This increases the rate at which non-MDR TB cases are diagnosed. The user can specify by what % the 
diagnostic rate is changed (currently limits are set at -100% to infinity). The coverage specifies the 
proportion of the non-MDR TB case population who experience this higher diagnostic rate.  
 
Increased Treatment success (non-MDR) 
This increases the treatment success for non-MDR TB cases. The Impact value is implemented as closing 
the gap between the current value for that year, and 100%. Coverage is implemented as increased case 
detection.  
 
MDR – increased diagnosis, linkage and treatment success 
This increases the rate at which MDR TB cases are diagnosed. The user can specify by what % the 
diagnostic rate is changed (currently limits are set at -100% to infinity).  
 
The user can also increase the % of diagnosed MDR TB cases that are linked into treatment, implemented 
as closing the gap between the current value for that year, and 100%. 
 
The % with successful treatment, is also implemented as closing the gap between the current value for that 
year, and 100%.  
 
The coverage specifies the proportion of the MDR TB case population who experience this higher 
diagnostic rate, linkage to care or successful treatment. 
 
IPT for HIV positive individuals 
We assume IPT provides 35% protection of progression to disease during therapy, assuming that no TST is 
carried out, following results from the most recent systematic literature review by Akolo et al. and a recent 
trial on the effect of IPT in a cohort of HIV positive patients receiving ART. (21, 22). This value can be 
adjusted in the ‘Impact’ tab. The protection is assumed to stop immediately post therapy. Biologically there 
is no reason to assume an effect on the risk of progression from a new (re)infection after IPT cessation 
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therapy. Recent modelling work has suggested that the risk of reactivation is also unaffected in HIV positive 
individuals, i.e. patients are not cured of their existing infection (23).  
 
IPT coverage is implemented in TIME as part of ACF in HIV+ (option for on and/or off ART). The user can 
specify the coverage of IPT in each year in the Coverage tab of the Intervention editor. The user will need 
to specify coverage of ACF in this population, and IPT coverage will fit within the envelope of ACF coverage 
(e.g. 80% coverage of IPT means 80% of ACF coverage receives IPT). TIME assumes that patients starting 
on IPT will need to be screened for active TB before the provision of mono-therapy in that time-step and 
that patients already on IPT from a previous time-step are screened annually for active disease. For 
simplicity, no adjustment is made to the yield from ACF to account for the lower prevalence in the 
population already on IPT being rescreened for active disease.  
 
The TB disease probabilities for rapid progression and reactivation for HIV positive individuals are reduced 
by a factor (1-Imp*Cov). “Imp” is the impact factor (protection from IPT) inputed by the user in the Impact 
matrix and reflects the impact on progression rates of indivuduals who received IPT. “Cov” is the actual 
population-level change in the coverage of IPT, compared to the baseline year. 
 
Increased ART coverage 
Increases in ART coverage in the general population is modelled through the AIM module in Spectrum. 
ART coverage from AIM is emulated in Care and Control of TIME Impact so that users can make changes 
directly in the TIME module. Any changes to ART coverage made in AIM are automatically updated in 
TIME. TIME Impact assumes that those receiving ART experience the level of protection as specified in the 
Epidemiology in TIME Impact.  
 
HIV testing and ART initiation 
This intervention aims to model the increase in coverage of HIV testing and linkage to ART care for notified 
TB cases. 
 
In the Implementation/Coverage tab of the Intervention editor, the user can specify the coverage of HIV 
testing amongst notified TB cases and the proportion of those that are linked into ART care.  
 
The proportion of TB notifications, who are HIV+ and initiated on ART, is calculated by Coverage of 
test(t)*proportion linked to ART(t) and these are counted as “new ART patients”. Those started on ART 
experience the treatment success parameters for ART-specific TB cases found in the Care and Control 
editor as well as the ART parameters specified in the Epidemiology editor. 
	
Active Case Finding 
Users can implement active case finding in the general population. Currently active cases finding in high 
risk groups cannot be modelled because structures for risk groups (other than HIV) are not included in 
TIME v1.0 
 
ACF is split by HIV category (HIV-, HIV+ not on ART, HIV+ on ART) to allow for targeted ACF in these sub-
groups. The user is able to select which HIV stratum should be included in the ACF campaign. 
 
The ACF structure is set up as a copy of the general structure for passive case finding.  
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The ACF interface requires that the following parameters are entered: 
- The sensitivity of the algorithm that is used (for smear positive, smear negative and MDR TB) 
- The frequency of ACF campaigns (n per year, duration of 1 round, interval between rounds or the 
user can specify continuous ACF which is equivalent to 12x 1 month campaigns with no interval 
between). 
- Standard of TB care after diagnosis (relative to the linkage to care and treatment success in the 
standard care pathway found in the Care and Control tab).  
 
In the coverage tab the user must enter the proportion of the population tested in each round of ACF in 
each year. For each month in which ACF occurs a proportion of the prevalent pool of TB cases (given by 
the coverage divided by the length of the round) is tested and those diagnosed (based on specified 
sensitivity algorithm) are then distributed across the different paths diagnosed TB cases can take (not 
linked to care, treatment failure, treatment success, etc..).  
 
Preventive Therapy for HIV negative individuals 
To reflect successful preventive therapy for HIV negative individuals, a specific post-preventive therapy 
compartment has been implemented in TIME Impact. In this compartment, individuals are assumed to 
experience the same risk of reinfection as the rest of the population, but they cannot reactivate, and have 
the same level of immunity as those in the latent compartment.  
 
The coverage of preventive therapy in HIV- individuals is set to fit within the envelope of the ACF coverage. 
The user needs to specify the coverage for ACF in HIV- general population in order to be able to model the 
provision of PT to HIV- individuals.  
 
The user can specify the sensitivity of the chosen test used for screening for LTBI after selecting to include 
preventive therapy as part of the ACF campaign in the Active case finding tab and the protective efficacy of 
preventive therapy in HIV- individuals in the Impact tab (default is set 80%, reflecting high adherers in the 
UATD trial (24)). 
 
In the Coverage tab, the user can specify the proportion of HIV- individuals screened that complete the 
diagnosis (given that a proportion may be lost to follow-up before LTBI status has been confirmed), the 
proportion linked to LTBI care and the proportion that complete the full course of preventive therapy. 
 
The proportion of HIV- individuals that move from the latent compartment to the post-preventive therapy 
compartment is calculated as Coverage ACF(t)*Coverage LTBI Dx(t)*sensitivity*complete DX(t)*Linked to 
LTBI care(t)*Tx completion rate(t)*protective efficacy. The rest are assumed to remain in the latent 
compartment. 
 
As current Preventive Therapy include Isoniazid and Rifampicin, the TIME Impact model assumes that 
MDR latent categories are unaffected by preventive therapy. 
 
IPT for child household contacts of under 5 years old and ACF among household members of 
all ages 
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Current WHO policy is to provide all children of under 5 years old who are household contacts of an index 
case, in the absence of testing for infection. This inherently includes ACF in all household members of all 
ages. 
 
A systematic review/meta-analysis by Morrison et al (2008) suggests that 30.4% of all household contacts 
of under 5 years old are infected with Mtb (25). We also assume based on a recent review by Ayieko et al 
(2014) that the random effects RR of TB disease is 0.55 if completed 6 months of INH compared to those 
who did not receive IPT (26). 
 
In the intervention editor, the user specifies the coverage of the intervention (ie. the proportion of notified 
adult cases whose household will be investigated) as well as the proportion of under 5 year old contacts 
that complete the full course of INH. TIME pulls in the country-specific average number of under 5 year olds 
per household from the Child Health module.  
 
Since TIME models primary disease as an instantaneous event following infection, the benefit of IPT is split 
and moves a proportion of u5s from latent and a proportion from susceptible to the post-preventive therapy 
compartment. This is determined by the proportion of u5 household contacts that are infected with Mtb 
(30.4%) and the proportion that is either at risk of rapid progression to disease (85%) or at risk of remaining 
latently infected (15%) (expert opinion). 
 
The number of children under 5 years old that move from the susceptible compartment to the post-
preventive therapy compartment is given by (# notified adult cases)*(average # of u5s per 
household)*(proportion u5 infected)*(proportion progressing rapidly to disease)*(coverage of 
intervention)*(completion rate)*(protection). This number of u5s are removed from the active disease 
compartment at the end of the model run in each time-step, before counting the outputs. 
 
The number of children under 5 years old that move from the latent compartment to the post-PT 
compartment is given by (# notified adult cases)*(average # of u5 per household)*(proportion u5 
infected)*(proportion progressing to latent infection)*(coverage of intervention)*(completion 
rate)*(protection). 
 
Morrison et al. also suggest in their systematic review/meta-analysis that 4.5% of household contacts of an 
index case have active disease (25). For the ACF component, the user will need to specify the coverage of 
the intervention (ie. the proportion of notified adult cases whose household will be investigated, which will 
be the same as specified above), details for the screening algorithm (sensitivity, relative detection of SS- 
and relative detection of MDR) as well as the relative linkage to care and treatment success. 
 
 The average household size is pulled into TIME from the Child Health module. Additional cases picked up 
in the ACF is given by (# of notified adult cases)*(average household size-1)*(coverage of 
intervention)*(proportion active disease)*(sensitivity of algorithm) and these will enter the ACF care 
pathway. 
 
The ACF component is applied before the IPT in u5s in order to reflect the removal of active cases in that 
age group before the provision of IPT and to avoid the provision of mono-therapy to active cases. 
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8. Summary health measures 
 
TIME	v1.0	calculates	summary	health	measures	which	are	presented	as	absolute	number	of	years	of	life	lived	with	
disability	(YLD),	years	of	life	lost	(YLL)	and	disability-adjusted	life	years	(DALY).	
TIME	bases	its	calculations	on	the	following	formulae:	
!"# = %&'( 	×	+'(' ×	 1 + . /0&& 	
!"" = 	 #&'( 	×	"1(	×	(1 + .)/0&	(
	
'
	
& 	
Where,	#4"! = !"# + !""	and	therefore	#4"!5	6789:8.	 ∆#4"! = 	∆!"# +	∆!""	:	=	year	(where	first	year	count	starts	at	1).		<	=	health	state	stratified	by	TB	(active	vs.	no	disease),	HIV	status	(HIV+	vs.	HIV-),	CD4	category	(<50,	50-99,	100-199,	
200-249,	250-349,	350-499,	>500)	and	length	of	time	on	ART	(no	ART,	0-6	months,	7-12	months,	>12	months).	=	=	age	group.	%&'( 	=	The	number	of	individuals	(prevalence)	in	a	health	state	in	a	given	year	and	age	group.	#&'( 	=	Number	of	all-cause	deaths	in	each	health	state	in	a	given	year	and	age	group.	"1( 	=	The	life	expectancy	for	the	midpoint	in	a	given	age	group.	Default	is	to	use	country-specific	life	tables	stored	in	
DemProj,	but	users	can	select	the	option	for	using	a	standardized	life	table	adapted	from	Murray	et	al	2010.(27)	.	=	discount	rate.	Default	is	set	to	0,	but	can	be	adjusted	by	putting	in	the	discount	rate	in	the	form	of	a	proportion	
in	the	configuration	window	(e.g.	a	discount	rate	of	3%	should	be	inputted	as	0.03).	+' 	=	disability	weight	for	each	health	state	(Table	4)	adapted	from	Salomon	et	al.	2012.(28)		
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Table	4.	Disability	weights	by	health	state	
	
HIV		 TB	
HIV	state	 Active	TB	 Non	active	TB		
HIV	negative		 0.331	 0.000	
HIV	positive	not	
on	ART	
CD4	sub-
category	
(cells/uL)	
CD4	<	50		
0.547	 0.547	CD4	50-99	
CD4100-199	
CD4	200-249	
0.399	 0.221	
CD4	250-349	
CD4	350-499	
0.331	 0.054	
CD4	>	500		
HIV	positive	on	ART		
0-6	months	
0.331	
	
0.053	
	 	
7-12	months	
>	12	months		
	
Data	for	CD4-specific	disability	weights	is	available	for	three	CD4	categories	(Table	4);	therefore,	we	assume	the	
same	disability	weight	across	CD4	categories	as	stratified	in	TIME,	based	on	available	data	(i.e.	there	is	no	evidence	
to	support	interpolation	between	categories).	Furthermore,	we	assume	a	constant	disability	weight	regardless	of	
length	of	time	on	ART,	as	per	available	data.	
	
TIME	v1.0	provides	absolute	number	of	years	of	life	lived	with	disability,	years	of	life	lost	and	DALYs,	by	year	and	
stratified	by	age	group.	The	user	will	need	to	make	use	of	external	software	(such	as	Excel)	for	further	analysis	of	the	
outputs,	such	as	calculation	of	DALYs	averted	due	to	an	intervention,	or	the	distribution	of	DALYs	between	children	
vs.	adults.	
	
9. Demography 
 
TIME Impact uses parameters from DemProj in order to create the modelled population. Births are 
introduced into the model and calculated directly in TIME by applying the ASFR and TFR from DemProj to 
women of 15-49 years old.  Ageing rates are calculated by taking the population of the final age (eg. 
Population of 9 year olds) in each age-bin and dividing it by the population of all ages in the age-bin (eg. 
Population of 5-9 year olds). Background mortality is calculated using life tables. The number of deaths in 
each age-bin is divided by the mid-year population of that age-bin to calculate the mortality rate. TB deaths 
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from TIME Impact are removed from overall background mortality in order to avoid double counting. 
International migration is currently ignored in TIME’s demographic model. 
 
10. Model Initialisation and population size adjustments 
Model initialisation  
The model is initialised in 3 phases which aim to create a stable TB epidemic in 1970 (pre-HIV) with 
approximately correct demographic composition and dynamics (birth and death rates).  
 
Phase 1: Demographics 
The 1970 age and sex distribution, together with TFR and ASFR as well as age specific death rates derived 
from life tables is used and run for 400 years to create an equilibrium/stable age structured population for 
1970.  
Phase 2: TB  
A 100 active TB cases are introduced into the population, with TB epidemiology parameters as set and the 
care and control parameter values as set for 1970. The model is then run for another 400 years to achieve 
equilibrium/stable disease state.  
Phase 3: Adjusting to fit 1970 population 
The population, which will be stable in age structure and TB incidence, is then adjusted to match the age 
and sex structure in 1970. In this adjustment, the age distribution of TB cases is maintained as in stage 2. 
Adjustment can be turned off in the configuration window starting at year 1970. 
 
The final population is then started in 1970 with the UN birth and death rates as well as the TB care and 
control parameters values in 1970.  
Phase 4: MDR initialisation 
The parameters are set to 0 until MDR is introduced into the population. The user can specify the date of 
MDR introduction, starting at 1971, and the proportion of retreatment and new cases that is MDR at that 
time.  
 
11. Fitting  
 
Fitting 
The fitting of TIME to a country’s specific TB epidemic profile is currently being done manually during the 
development phase to improve understanding of model behaviour. There is currently no automatic fitting 
algorithm that takes a model with default values and approximates a fully fitted model.  
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